Pfizer, Teva reach deal to allow generic Viagra
Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

New York: Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.
Pfizer says Teva will pay an undisclosed royalty for a license to produce a generic version of Viagra, one of New York-based Pfizer's best-selling drugs. Viagra generated about $1.14 billion in US sales last year.
Pfizer's patent protecting Viagra from generic competition expires in April 2020, but Teva will be allowed to launch its generic version Dec. 11, 2017.
Pfizer Inc. had sued Teva in 2010 over the Israeli drugmaker's plans to introduce a generic version of Viagra.
The patent protecting another erectile dysfunction drug, Eli Lilly and Co.'s Cialis, also expires in 2017.
PTI

Choke terror funding, keep international shipping lanes safe: Jaishankar at Asean Regional Forum
After Australia, New Zealand signs defence pact with Papua New Guinea as China expands in Indo-Pacific
Pakistan's deep state weaponising LeT to counter Asim Munir critic Maulana Fazlur Rehman: Report
No premium queues, 30-minute target: What changes for Indian passport applicants in UAE
'We don't need straits': Trump says Iran war isn't about Hormuz as US strikes for 12th night

